TABLE 1.
Molecule | Role(s) | Method(s) of proof | Reference(s) |
---|---|---|---|
BAFF | Mediating antibody response to TD and TI antigens | Immunization of BAFF−/− mice with TD and TI antigens | 6, 9, 68, 69 |
Augmenting antibody responses against vaccines as an adjuvant | Immunization of exptl animals with BAFF-containing vaccines | 7, 90–94 | |
APRIL | Inducing IgA isotype switch and production in response to TD and TI-I antigens | Systemic and mucosal immunization of normal, APRIL−/−, and APRIL-transgenic mice with TD and TI antigens | 19, 71, 72 |
Augmenting antibody responses against vaccines as an adjuvant | Immunization of exptl animals with APRIL-containing vaccines | 91, 92 | |
Immunization of APRIL Tg mice with TD and TI-II antigens | 20 | ||
BAFF-R | Mediating antibody response to TD and TI antigens | Immunization of BAFF-R−/− mice with TD and TI antigens | 6, 9, 68, 69 |
TACI | Mediating antibody response to TI-II antigens | Immunization of TACI−/− mice with TI-II antigens or CVID patients with polysaccharide vaccines | |
TACI expression levels determine antibody responses to TI-II antigens | Responses of newborn mice and XID mice to TI-II antigens | 35, 50, 52, 73–75, 79, 80 | |
Mediating TD antigen-specific plasma cell survival | Immunization of TACI−/− mice with TD antigens | 85, 89 | |
Controlling expansion of Tfh and GC cells | Immunization of HIV-infected patients with influenza vaccine | ||
BCMA | Contributing to long-term survival of antigen-specific bone marrow plasma cells | Immunization of BCMA−/− mice with a TD antigen | 31 |
TD, T cell dependent; TI, T cell independent; TI-II, TI type II; APRIL Tg, APRIL transgenic; CVID, combined variable immunodeficiency; XID, X-linked immunodeficient; Tfh, T follicular helper; GC, germinal center; HIV, human immunodeficiency virus.